



Commonwealth
of Australia

Letters patent

Patents Act 1990

No.
728438

STANDARD PATENT

I, Vivienne Joyce Thom, Commissioner of Patents, grant a Standard Patent with the following particulars:

Names and Addresses of Patentees:

Abbot F. Clark, 5603 Rachel Court Arlington TX 76017 United States Of America
Robert J. Wordinger, 411 Summit Ridge Drive Euless TX 76039 United States Of America

Names of Actual Inventors: Abbot F. Clark and Robert J. Wordinger

Title of Invention: Methods for diagnosing glaucoma and discovering anti-glaucoma drugs

Application Number: 52617/98

Term of Letters Patent: Twenty years commencing on 14 November 1997

Priority Details:

Number 60/033227	Date 5 December 1996	Filed with UNITED STATES OF AMERICA
----------------------------	--------------------------------	---

BEST AVAILABLE COPY

Dated this 26 day of April 2001

V.J.THOM
COMMISSIONER OF PATENTS



(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199852617 B2
(10) Patent No. 728438

(54) Title
Methods for diagnosing glaucoma and discovering anti-glaucoma drugs

(51)⁷ International Patent Classification(s)
C12Q 001/68

(21) Application No: 199852617

(22) Application Date: 1997.11.14

(87) WIPO No: WO98/24932

(30) Priority Data

(31) Number 60/033227 (32) Date 1996.12.05 (33) Country US

(43) Publication Date : 1998.06.29

(43) Publication Journal Date : 1998.08.20

(44) Accepted Journal Date : 2001.01.11

(71) **Applicant(s)**
Abbot F. Clark; Robert J. Wordinger

(72) Inventor(s)
Abbot F. Clark; Robert J. Wordinger

(72) Inventor(s)
Abbot F. Clark; Robert J. Wordinger

(74) Agent/Attorney
GRIFFITH HACK, GPO Box 1285K, MELBOURNE VIC 3001

(56) Related Art
WO 96/33287
WO 96/14411
JOURNAL OF GLAUCOMA, V.4, 1995, PP354-369

BEST AVAILABLE COPY



<p>(51) International Patent Classification ⁶ : C12Q 1/68</p>		<p>A1</p>	<p>(11) International Publication Number: WO 98/24932</p> <p>(43) International Publication Date: 11 June 1998 (11.06.98)</p>
<p>(21) International Application Number: PCT/US97/21054</p> <p>(22) International Filing Date: 14 November 1997 (14.11.97)</p>		<p>(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p>	
<p>(30) Priority Data: 60/033,227 5 December 1996 (05.12.96) US</p> <p>(71)(72) Applicants and Inventors: CLARK, Abbot, F. [US/US]; 5603 Rachel Court, Arlington, TX 76017 (US). WORDINGER, Robert, J. [US/US]; 411 Summit Ridge Drive, Euless, TX 76039 (US).</p> <p>(74) Agents: YEAGER, Sally, S. et al.; Alcon Laboratories, Inc., Patent Dept., Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).</p>		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: METHODS FOR DIAGNOSING GLAUCOMA AND DISCOVERING ANTI-GLAUCOMA DRUGS</p> <p>(57) Abstract Methods for diagnosing glaucoma and for screening therapeutic agents for their usefulness in treating glaucoma based on the detection of aberrant expression of beta glucocorticoid receptor (GRbeta).</p>			
<p>BEST AVAILABLE COPY</p>			

METHODS FOR DIAGNOSING GLAUCOMA AND DISCOVERING ANTI-GLAUCOMA DRUGS

Priority is claimed from the provisional application, U.S. Patent Application Serial No. 60/033227 filed December 5, 1996.

Background of the Invention

Glaucoma is usually diagnosed by monitoring a patient's visual field loss, changes in the appearance of their optic disc, and their intraocular pressure. Glaucoma is currently treated using one or more of three strategies to lower the elevated intraocular pressure associated with the disease: with pharmaceuticals (such as beta-blockers, carbonic anhydrase inhibitors, and miotics), with laser trabeculoplasty, and/or with glaucoma filtration surgery. All of these therapies indirectly lower intraocular pressure but do not address the underlying disease process occurring in the trabecular meshwork. It would be advantageous to be able to diagnose glaucoma before a patient begins experiencing a loss in their visual field and deterioration of their optic disc.

There is a large body of evidence suggesting that glucocorticoids are involved in the generation of ocular hypertension and glaucoma. See Clark, A. F., *Journal of Glaucoma*, "Steroids, Ocular Hypertension, and Glaucoma," 4:354-369, 1995. Several investigators have shown that the human trabecular meshwork (TM) contains the classical glucocorticoid receptor (GR α). See Weinreb, et al., *Invest. Ophthalmol. Vis. Sci.*, "Detection of Glucocorticoid Receptors in Cultured Human Trabecular Cells," 21:3, 403-407, 1981, and Hernandez, et al., *Invest. Ophthalmol. Vis. Sci.*, "Glucocorticoid Target Cells in Human Outflow Pathway: Autopsy and Surgical Specimens," 24:1612-1616, 1983. Recently, the expression of an alternatively spliced form of the human glucocorticoid receptor (GR β) was discovered in non-ocular tissues and cells. See Bamberger, et al., *The Journal of Clinical Investigation*, "Glucocorticoid Receptor β , a Potential Endogenous Inhibitor of Glucocorticoid Action in Humans," 95:2435-2441, 1995, and Oakley, et al., *The Journal of Biological Chemistry*, "The Human Glucocorticoid Receptor β Isoform," 271:16, 9550-9559, 1996. This alternatively spliced form of the glucocorticoid receptor (GR) is expressed as a protein which no longer binds glucocorticoids, but is able to interfere with the activated form of the normal glucocorticoid receptor and block or alter physiological functions of the glucocorticoid receptor.

BEST AVAILABLE COPY

Summary of the Invention

The present invention is directed to methods for diagnosing glaucoma by testing a person for aberrant GR β expression. Also set forth are methods for screening for therapeutic agents useful for treating glaucoma.

Description of Preferred Embodiments

Surprisingly, it has been found that cultured human trabecular meshwork cell lines derived from glaucomatous donors express mRNA for both an alternate splice form of the human glucocorticoid receptor (GR β), as well as the normal glucocorticoid receptor (GR α), whereas normal TM cell lines only express mRNA for GR α . It is believed that the elevated intraocular pressure associated with primary open-angle glaucoma may be due to the aberrant expression of GR β in the trabecular meshwork. Therefore, determining that an individual abnormally expresses GR β in their trabecular meshwork or other tissues can lead to a diagnosis of glaucoma. Also, this discovery can be used to determine whether agents have therapeutic value in treating glaucoma by determining whether they interact with GR β or alter the expression of GR β . This can be done using ligand binding assays or GR β functional assays.

Diagnosing aberrant GR β expression or defects in the GR gene which encodes GR β can be done by using procedures well known to those skilled in the art. See Caskey, C. T., *J.A.M.A.*, "Molecular Medicine. A Spin-off From the Helix," 269:15, 1986-1992, 1993. For example, subjects could be screened for the presence of a genetic defect in GR β by analyzing the DNA derived from peripheral blood leukocytes. Types of DNA analyses could include, but would not be limited to: restriction fragment length polymorphisms (RFLP), single-stranded conformation polymorphisms (SSCP), polymerase chain reaction (PCR), denaturing gradient gels, allele specific oligonucleotide ligation assay, and allele specific hybridization assay. In addition, trabecular meshwork, or other relevant cells from subjects could be analyzed for GR β expression by a number of techniques such as reverse-transcription polymerase chain reaction (RT-PCR), immunoassays, GR functional assays, etc.

In this specification, except where the context requires otherwise, the words "comprise", "comprises", and "comprising" mean "include", "includes", and "including", respectively, i.e. when the invention is described or defined as comprising specified features, various embodiments of the same invention may also include additional features.



We Claim:

1. A method for diagnosing glaucoma which comprises detecting aberrant GR β expression or defects in a GR gene which encodes GR β .
- 5 2. The method of Claim 1 wherein GR gene defects are detected by a method selected from the group of assays consisting of: restriction fragment length polymorphism (RFLP), single-stranded conformation polymorphism (SSCP), polymerase chain reaction (PCR), denaturing gradient gel, allele specific oligonucleotide ligation, and allele specific hybridization.
- 10 3. A method for diagnosing glaucoma, which comprises detecting genetic changes in the GR gene leading to altered GR β expression.
- 15 4. A method for diagnosing glaucoma, which comprises detecting genetic changes outside the GR gene which lead to altered GR β expression.
- 20 5. A method for determining whether an agent is useful for treating glaucoma by determining whether it interacts with GR β or alters the expression of GR β .

BEST AVAILABLE COPY